Centogene N.V. Net Assets
Centogene N.V. net assets. Based on the latest financial reports, Centogene N.V. (CNTGF) has net assets worth $-25.28 Million USD as of December 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($77.16 Million) and total liabilities ($102.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Centogene N.V. growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-25.28 Million |
| % of Total Assets | -32.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 177.22 |
Net Assets of Centogene N.V. (2020–2023)
Net assets of Centogene N.V. from 2020 to 2023. This chart illustrates how Centogene N.V.'s net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Centogene N.V. to measure how much of total assets are equity-financed.
Annual Net Assets for Centogene N.V. (2020–2023)
The table below shows the annual net assets of Centogene N.V. from 2020 to 2023. For live market cap and overall valuation, see Centogene N.V. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-25.28 Million | -441.14% |
| 2022-12-31 | $7.41 Million | -72.81% |
| 2021-12-31 | $27.26 Million | -58.02% |
| 2020-12-31 | $64.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Centogene N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11332900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Centogene N.V. Net Assets Breakdown (December 2023)
Centogene N.V. net assets breakdown by equity component as of December 2023.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $151.79 Million | % |
| Total Equity | $-25.28 Million | 100.00% |
Centogene N.V. Competitors by Market Cap
The table below lists competitors of Centogene N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
$3.48 Million |
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
$3.48 Million |
|
Anagenics Ltd
AU:AN1
|
$3.49 Million |
|
The Biotech Growth Trust PLC
LSE:BIOG
|
$3.49 Million |
|
Thunderstruck Resources Ltd
V:AWE
|
$3.48 Million |
|
Komarkcorp Bhd
KLSE:7017
|
$3.48 Million |
|
STRATHMORE PLUS URANIUM
F:TO3
|
$3.48 Million |
|
Silver Grail Resources Ltd
V:SVG
|
$3.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Centogene N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,411,000 to -25,282,000, a change of -32,693,000 (-441.1%).
- Net loss of 35,532,000 reduced equity.
- Other factors increased equity by 2,839,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.53 Million | -140.54% |
| Other Changes | $2.84 Million | +11.23% |
| Total Change | $- | -441.14% |
Book Value vs Market Value Analysis
This analysis compares Centogene N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $2.94 | $0.12 | x |
| 2021-12-31 | $1.21 | $0.12 | x |
| 2022-12-31 | $0.27 | $0.12 | x |
| 2023-12-31 | $-0.87 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Centogene N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -73.21%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-158.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -33.86% | -57.18% | 0.26x | 2.31x | $-28.48 Million |
| 2021 | -169.66% | -109.50% | 0.46x | 3.34x | $-48.97 Million |
| 2022 | -429.65% | -67.07% | 0.51x | 12.52x | $-32.58 Million |
| 2023 | 0.00% | -73.21% | 0.63x | 0.00x | $-33.00 Million |
Industry Comparison
This section compares Centogene N.V.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $642,049,271
- Average return on equity (ROE) among peers: -86.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Centogene N.V. (CNTGF) | $-25.28 Million | -33.86% | N/A | $3.48 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $43.76 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $3.63 Million |
| Applied DNA Sciences Inc (APDN) | $-1.47 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.61 Million | -317.61% | 3.51x | $222.10 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $14.35 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $167.75 Million | -24.78% | 0.80x | $4.66 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $96.42 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $41.31 Million | -46.25% | 0.10x | $9.42 Million |
About Centogene N.V.
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA … Read more